Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors

By sjmartinez • May 3, 2025

Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Carrillo RB, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May 1;10(5):105081. doi: 10.1016/j.esmoop.2025.105081. Epub ahead of print. PMID: 40315659.

Tags: CE regimen, Hematology/Oncology, high-dose chemotherapy, prognostic models, Publications, relapsed germ cell tumors, TICE regimen

Related Posts

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando[...]

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R,[...]

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]